MRK - Merck & Co Inc
(NaN%)
SNP 500DOW 30
Sell
Weak Growth
38%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -40.26%
Operating Income Growth is -92.01%
Net Income Growth is -77.43%
Earnings Per Share (EPS) Growth is -82.42%
Net Margin is 3.76%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 1.25
Debt Ratio is 0.32
Current Debt to Net Income Ratio is 0.65
Total Debt to Total Assets Ratio is 0.32
Cash Flow is MODERATE
Cash from Operations Growth is -5.84%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Merck & Co Inc (MRK) - https://www.merck.com/
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry -
Sector -
CEO -
Employees - 67,000
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.